iBio (NYSEA:IBIO) expanded its AI-powered technology stack with the launch of EngageTx, a proprietary T-cell engager antibody panel designed for developing bispecific antibodies for immuno-oncology applications. Through...
Genetic Engineering & Biotechnology News (GEN), in a feature article, outlines iBio’s (NYSE American:IBIO) transition from a contract development and manufacturing organization and cGMP biologics manufacturer to a...
JMP Securities, in a new report, writes that the promising mechanistic and clinical activity for Roche’s drug candidate, RG6292, should support advancement of iBio’s (NYSEA:IBIO) IBIO-101. IBIO-101 is an anti-CD25...
iBio (NYSEA:IBIO) announced the discovery of a panel of CD3 T-cell binding antibodies, representing an important first step for the company into bispecific immuno-oncology therapies. T-cell-redirecting bispecific...
iBio (NYSEA:IBIO) advanced its anti-CCR8 antibody immuno-oncology program into preclinical in vivo testing. CCR8, a member of the G protein-coupled receptor (GPCR) family, is expressed by T-regulatory cells (Tregs) that...
iBio (NYSE American:IBIO) selected MUC16 as the target of its latest immuno-oncology program. MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and...
iBio (NYSEA:IBIO) received a patent from the U.S. Patent and Trademark Office issued a patent entitled, “Machine Learning Method For Protein Modelling To Design Engineered Peptides,” which covers a machine learning...
iBio (NYSEA:IBIO) will present two posters about its intelligence-powered RubrYc discovery engine at the Antibody Engineering and Therapeutics Conference in San Diego on Dec. 4-8. The conference features the latest...
iBio (NYSEA:IBIO) announced it is seeking to divest its contract development and manufacturing organization, iBio CDMO, in order to complete its transformation into an antibody discovery and development company...
iBio (NYSEA:IBIO) closed the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, marking an important step in iBio’s mission to bring more, and better, immunotherapies to the...